Inhibition of human antigen-specific memory B cell response in vitro by a diphtheria toxin-related interleukin 2 fusion protein
Recombinant diphtheria toxin-related interleukin-2 fusion protein (DAB 486IL-2) is specifically cytotoxic for cells bearing the high-affinity IL-2 receptor (p55/75). We evaluated the effects of DAB 486IL-2 on the generation of tetanus toxoid(TT)-specific IgG antibody-forming cells in 6-day coculture...
Gespeichert in:
Veröffentlicht in: | Cellular immunology 1991-02, Vol.132 (2), p.481-493 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Recombinant diphtheria toxin-related interleukin-2 fusion protein (DAB
486IL-2) is specifically cytotoxic for cells bearing the high-affinity IL-2 receptor (p55/75). We evaluated the effects of DAB
486IL-2 on the generation of tetanus toxoid(TT)-specific IgG antibody-forming cells in 6-day cocultures of human splenocytes and TT-coupled Sepharose beads. The results indicate that a significant portion (30–75%) of the anti-tetanus toxoid IgG response
in vitro was susceptible to inhibition by 10
−10
M DAB
486IL-2. The inhibition required both the IL-2 portion of the fusion protein and an active toxin moiety and was greater when the IL-2 toxin was added on Day 3 as compared with Day 0 of culture. The induction of the p55 (Tac) subunit of the IL-2R was demonstrable by two-color flow cytometry on a small percentage (5%) of B cells and on a higher percentage (10%) of non-B cells 3 days after exposure to TT-coupled Sepharose. Short-term (2 hr) treatment of T and B cell subpopulations separated on Day 3 of culture followed by remixing indicated that while activated T helper cells were most strongly inhibited by DAB
486IL-2, up to 50% of the TT-specific IgG response was inhibited by treatment of B cells alone with DAB
486IL-2. Our results suggest that a strategy of eliminating human memory B cells by a combination of antigen activation and properly timed administration of a recombinant lymphokine-toxin fusion protein is feasible. |
---|---|
ISSN: | 0008-8749 1090-2163 |
DOI: | 10.1016/0008-8749(91)90044-C |